Reduction in pediatric rotavirus-related hospitalizations after universal rotavirus vaccination in belgium

Pediatric Infectious Disease Journal

Volumn 30, Issue 7, 2011, Pages

  Raes, Marc ^a   Strens, Danielle ^b   Vergison, Anne ^c   Verghote, Marc ^d   Standaert, Baudouin ^e  

^a VIRGA JESSE HOSPITAL   (Belgium)

^b Deloitte   (Belgium)

^c UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^d Centre Hospitalier Regional de Namur   (Belgium)

^e GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Children; Gastroenteritis; Hospitalization; Rotavirus; Vaccination

Indexed keywords

ROTAVIRUS VACCINE;

ACUTE GASTROENTERITIS; ARTICLE; BELGIUM; CHILD; FECES ANALYSIS; GROUPS BY AGE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; PEDIATRIC HOSPITAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ROTAVIRUS INFECTION; VACCINATION;

BELGIUM; CHILD, PRESCHOOL; FECES; FEMALE; GASTROENTERITIS; HOSPITALIZATION; HUMANS; INFANT; MALE; PREVALENCE; RETROSPECTIVE STUDIES; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; VACCINATION;

EID: 79959730149     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e318214b811     Document Type: Article

References (30)

1. Parashar UD, Bresee JS, Gentsch JR, et al. Rotavirus Emerg Infect Dis. 1998;4:561-570.
2. Gimenez-Sanchez F, Gado-Rubio A, Martinon-Torres F, et al. Multicenter prospective study analysing the role of rotavirus on acute gastroenteritis in Spain. Acta Paediatr. 2010;99:738-742.
3. Williams CJ, Lobanov A, Pebody RG. Estimated mortality and hospital admission due to rotavirus infection in the WHO European region. Epidemiol Infect. 2009;137:607-616.
4. Soriano-Gabarro M, Mrukowicz J, Vesikari T, et al. Burden of rotavirus disease in European Union countries. Pediatr Infect Dis J. 2006;25:S7-S11.
5. Raes M, Aerssens P, Alliet P, et al. Rotavirus gastroenteritis: epidemiological data from a regional hospital in Belgium. Eur J Pediatr. 2008;167:71-73.
6. Bilcke J, Van Damme P, De Smet F, et al. The health and economic burden of rotavirus disease in Belgium. Eur J Pediatr. 2008;167:1409-1419.
7. Standaert B, Harlin O, Desselberger U. The financial burden of rotavirus disease in four countries of the European Union. Pediatr Infect Dis J. 2008;27:S20-S27.
8. Vesikari T, Van Damme P, Giaquinto C, et al. European Society for Paediatric Infectious Diseases/European Society for Paediatric Gastroenterology, Hepatology, and Nutrition evidence-based recommendations for rotavirus vaccination in Europe: executive summary. J Pediatr Gastroenterol Nutr. 2008;46:615-618.
9. Vesikari T, Van Damme P, Giaquinto C, et al. European Society for Paediatric Infectious Diseases/European Society for Paediatric Gastroenterology, Hepatology, and Nutrition evidence-based recommendations for rotavirus vaccination in Europe. J Pediatr Gastroenterol Nutr. 2008;(46 suppl 2):S38-S48.
10. World Health Organization. Meeting of the immunization Strategic Advisory Group of Experts, April 2009-conclusions and recommendations. Wkly Epidemiol Rec. 2009;84:220-236.
11. Vesikari T, Karvonen A, Puustinen L, et al. Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants. Pediatr Infect Dis J. 2004;23:937-943.
12. Vesikari T, Karvonen A, Prymula R, et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet. 2007;370:1757-1763.
13. Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med. 2006;354:23-33.
14. Raes M, Strens D, Vergison A, et al. Second year post-rotavirus vaccination in Belgium: impact on rotavirus-positive stool samples in hospitalised children. In: 28th annual meeting, European Society for Paediatric Infectious Diseases (ESPID); May 4-8, 2010; Nice, France.
15. Van Damme P. Early experience with routine use of rotavirus vaccines in Europe. In: 8th International Rotavirus Symposium; June 3-4, 2008; Istanbul, Turkey.
16. Fruytier A, Van Schoor J, Standaert B. Vaccination with RIX4414 is cost-effective in a Belgian setting (abstract PIH3). Value Health. 2006;9:A253.
17. Bilcke J, Van Damme P, Beutels P. Cost-effectiveness of rotavirus vaccination: exploring caregiver(s) and ‘no medical care’ disease impact in Belgium. Med Decis Making. 2009;29:33-50.
18. Standaert B, Parez N, Tehard B, et al. Cost-effectiveness analysis of vaccination against rotavirus with RIX4414 in France. Appl Health Econ Health Policy. 2009;6:199-216.
19. Martin A, Batty A, Roberts JA, et al. Cost-effectiveness of infant vaccination with RIX4414 (Rotarix) in the UK. Vaccine. 2009;27:4520-4528.
20. De Cauwer H, Mortelmans L, d'Orio V. Belgische ziekenhuizen onvoldoende voorbereid op pandemie. 2009. Available at: http://www.hospitals.be/pdf/vol7n2p14.pdf. Accessed October 14, 2010.
21. Flem E, Vainio K, Dollner H, et al. Rotavirus gastroenteritis in Norway: analysis of prospective surveillance and hospital registry data. Scand J Infect Dis. 2009;41:753-759.
22. Centers for Disease Control and Prevention (CDC). Delayed onset and diminished magnitude of rotavirus activity-United States, November 2007-May 2008. Morb Mortal Wkly Rep. 2008;57:697-700.
23. Centers for Disease Control and Prevention (CDC). Reduction in rotavirus after vaccine introduction-United States, 2000-2009. Morb Mortal Wkly Rep. 2009;58:1146-1149.
24. Gimenez-Sanchez F, Salvador-Sanchez J, Cobos-Carrascosa E, et al. Decline in rotavirus hospitalized cases in Spain after the introduction of oral rotavirus vaccines. In: 27th annual meeting, European Society for Paediatric Infectious Diseases (ESPID); June 9-13, 2009; Brussels, Belgium.
25. Paulke-Korinek M, Rendi-Wagner P, Kundi M, et al. Universal mass vaccination against rotavirus gastroenteritis: impact on hospitalization rates in Austrian children. Pediatr Infect Dis J. 2010;29:319-323.
26. Lambert SB, Faux CE, Hall L, et al. Early evidence for direct and indirect effects of the infant rotavirus vaccine program in Queensland. Med J Aust. 2009;191:157-160.
27. Belshaw DA, Muscatello DJ, Ferson MJ, et al. Rotavirus vaccination one year on. Commun Dis Intell. 2009;33:337-340.
28. Zeller M, Rahman M, Heylen E, et al. Rotavirus incidence and genotype distribution before and after national rotavirus vaccine introduction in Belgium. Vaccine. 2010;28:7507-7513.
29. Atchison C, Lopman B, Edmunds WJ. Modelling the seasonality of rotavirus disease and the impact of vaccination in England and Wales. Vaccine. 2010;28:3118-3126.
30. Standaert B, Strens D, Van Bellinghen LA, et al. Comparing the model predicted vaccine impact against rotavirus hospitalisation with observed data in Belgium. In: 13th Annual European Congress, International Society for Pharmacoeconomics and Outcomes Research (ISPOR); November 6-9, 2010; Prague, Czech Republic.